Clarifications on the company's leadership transition
Chris Cashman's stepping down from his long tenure at the helm of Marinus prompted mixed responses, with some people fearing internal discord or poor prospects for the company's neuroactive investigational drug ganaxolone. I had an opportunity to discuss the leadership transition with Marinus' management team, which yielded the following insights.
Chris joined Marinus as a member of the BoD and subsequently assumed the role of interim CEO following the sudden death of the company's first CEO. As Chris grew into his role, his interim role turned into a full